A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in the United States of America (USA). This is an in-patient trial investigating stepwise dose increase in a period of up to 3-weeks followed by a 10-week out-patient maintenance period. A telephone contact visit is scheduled as a follow-up for the final clinic visit. A subject's participation in this trial would be expected to be up to 16 weeks.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Type 2 diabetes diagnosis at least 2 years ago

• Body Mass Index (BMI): 26-40 kg/m^2 (both inclusive)

• HbA1c: 7.5-10% (both inclusive)

• FPG values at least 140 mg/dl (7.8 mmol/l)

Exclusion Criteria:

• Use of drugs, which may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action or glucose utilization (steroids or non-specific beta-blockers)

• Current addiction to alcohol or substances of abuse or positive results on urine screen for drug and alcohol use

• Known or suspected allergy to trial products or related products